IP Licensing Power BMG Pharma’s strong IP portfolio anchored by Hyaluromimethic Technology enables out-licensing and co-development with global partners across dermatology, dermal aesthetics, oral care, osteoarthritis, and women’s health.

Injectable Platform Recent SHLF injectable platform development positions BMG for global registrations and launches, creating BD opportunities with pharma and contract manufacturers seeking to add injectable hyaluronic-based therapies.

Product Portfolio Growth Current launches such as BMG0705 Nasal Spray, BMG0703A Mouth Rinse, and NormAdvance acne kit demonstrate a diversified pipeline ripe for licensing, private-label manufacturing, or distribution partnerships.

Global Expansion Potential As a small-to-mid sized Italian biotech with a global licensing model and visible funding, BMG is well positioned to partner with international distributors and contract manufacturers to accelerate market access.

Multi-Vertical BD The company targets dermatology, dermal aesthetics, oral care, osteoarthritis, and women’s health, offering cross-sell opportunities to clinics, cosmetic brands, dental suppliers, and health retailers seeking to license or co-develop Hyaluromimethic-based products.